Philadelphia, July 5 – Bringing leading next generation of immuno-oncology experts together under one roof, 2nd Annual Next Gen Immuno-Oncology Congress will target challenges, novel developments associated with Monoclonal and Bispecific Antibodies Cell Therapy Immune Checkpoint Inhibitors. The congress will span over two days from September 19 to September 20 in Philadelphia – USA hosting 45 expert speakers, 15+ sponsors and 250+ professionals from research institutes, pharmaceutical, bio-pharmaceutical and biotechnology companies.

The conference agenda will be divided in 3 streams and focussed various aspects of Immuno-oncology filed such as monoclonal and bispecific Antibodies, cell therapy and immune checkpoint inhibitors. Speaker panel of over 45 experts will be presenting their immune-oncology research, new case studies, implementations of antibody projects in development.

Leveraging on ongoing development in immunotherapies, such as antibody drug conjugates, immune checkpoint inhibitors, bispecific antibodies and cell therapies, the congress agenda will share insights from leading organisations such as Merck, Bionavigen, Celgene, Pfizer, Omniseq, Transcure BioServices, NIH, Palleon Pharma, TG Therapeutics.

The agenda consists dedicated sessions discussing updates on development of monoclonal ABs and Bispecific Abs, Immune Checkpoint Inhibitors and Combinations, Preclinical and Translational Immuno-Oncology Developments, Biomarkers and Cancer Vaccines, Next Gen CAR-T Cell Therapy, T-Cell Therapy, Tumour Microenvironment and Oncolytic Viruses.

The event overview, registration details and complete speaker list are available on the official website. You can also download the complete agenda to identify the potential interest in the conference on this page – https://bit.ly/2JaPDIU or you can directly email on [email protected] asking for more details, your queries and provide feedback.